Depression clinical trials, in English

Study Description: This study examines relations between neurocognitive and clinical features of pediatric anxiety disorders. The study uses neuro-cognitive tasks, functional magnetic resonance imaging (fMRI), as well as magneto- and electro-encephalography (M/EEG).

NCT00018057 · Official ClinicalTrials.gov record · National Institute of Mental Health (NIMH)

Background: There are no good treatments for people considering suicide. Researchers want to study suicide with questions, blood tests, brain imaging, and sleep studies.

NCT02543983 · Official ClinicalTrials.gov record · National Institute of Mental Health (NIMH)

The specific aims of the study are: Primary: To determine the presence and regional distribution of microglial activation, as assessed by Fluorine-18 (18F) labeled "Peripheral Benzodiazepine Receptor 06" (PBR06) -PET, in subjects with active Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), and Alzheimer's Disease (AD) as compared to healthy controls Secondary: 1. To assess the relationship between microglial activation and clinical variables including disease severity and comorbidities (such as pain, fatigue and/or depression), as well as clinical MRI findings (such as lesions and atrophy) 2.

NCT02649985 · Official ClinicalTrials.gov record · Brigham and Women's Hospital

Background: Most medications that treat depression take weeks or months to work. Researchers want to develop fast-acting treatments.

NCT03065335 · Official ClinicalTrials.gov record · National Institute of Mental Health (NIMH)

Background: Most drugs that treat mood disorders take a long time to work. Certain receptors in the brain might help ketamine work.

NCT03973268 · Official ClinicalTrials.gov record · National Institute of Mental Health (NIMH)

Background: More than 12,000 people have taken part in research at the Experimental Therapeutics \& Pathophysiology Branch at the National Institute of Mental Health Intramural Program. This has led to advances in the treatment of depression, bipolar disorder, and suicide risk.

NCT04877977 · Official ClinicalTrials.gov record · National Institute of Mental Health (NIMH)

The main purpose of this study is to investigate the effects of ketamine on decision-making and emotion processing in a sample of individuals diagnosed with Major Depressive Disorder (major depression).

NCT05327699 · Official ClinicalTrials.gov record · Emory University

The purpose of this research is to study the safety and effects of single-dose psilocybin 25mg versus an active dummy treatment (placebo) (single dose niacin 100mg) in the treatment of anxiety, depression, and existential distress (i.e., loss of meaning and hope; fear of death) in advanced cancer (i.e., stage 3 or 4). Study medications will be administered in conjunction with brief psychotherapy that is designed to treat anxiety, depression and existential distress in advanced cancer.

NCT05398484 · Official ClinicalTrials.gov record · NYU Langone Health

The study will consist of a 24-week-long trial examining outcomes in patients with Major Depressive Disorder and suicidal ideation who will receive intravenous (IV) ketamine and intranasal (IN) esketamine, compared to a large sample of matched historical controls. Patients will be recruited from an inpatient psychiatric unit.

NCT05450432 · Official ClinicalTrials.gov record · Massachusetts General Hospital

Background: Nicotine dependence leads to about 480,000 deaths every year in the United States. People with major depressive disorder (major depression) are twice as likely to use nicotine compared to the general population.

NCT05538910 · Official ClinicalTrials.gov record · National Institute on Drug Abuse (NIDA)

Amyotrophic lateral sclerosis (ALS) is a degenerative neurological disease that causes progressive motor disability and is life threatening within a few years. The severity of the disease, the progressive loss of autonomy that leads to dependence on family and caregivers, and the lack of effective treatment sometimes leads patients to a loss of hope and to dark thoughts.

NCT05632757 · Official ClinicalTrials.gov record · Assistance Publique Hopitaux De Marseille

Background: Mood disorders, such as bipolar disorder, can have serious effects on a person s life. People with bipolar disorder are more likely to have heart disease and abuse substances.

NCT05669703 · Official ClinicalTrials.gov record · National Institute of Mental Health (NIMH)

The goal of this randomly assigned controlled trial is to measure the potential of a customized digital cognitive training intervention to target aspects of brain function in apathy of late-life depression and reduce symptoms of apathy and related cognitive and behavioral deficits. The investigators hypothesize that 4 weeks of a customized digital cognitive training program will lead to changes in brain connectivity, apathy severity, and cognitive control performance.

NCT05877885 · Official ClinicalTrials.gov record · AdventHealth

The goal is to study the effect of lithium compared to cariprazine in patients with depression in a bipolar disease. The main question it aims to answer is: Difference in change between the two groups from baseline to after 8 weeks treatment on Hamilton Ratings Scale for Depression, 6-item version (HDS-6) you would be randomly assigned to treatment with either lithium or cariprazin.

NCT05913947 · Official ClinicalTrials.gov record · Aalborg University Hospital

The proposed study will assess the combined effect of perampanel and ketamine on the anti-depressant response in individuals with treatment resistant depression. this study wants to test the hypothesis that stimulation of Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid receptors (AMPAR) is critical to the anti-depressant response of ketamine.

NCT05915013 · Official ClinicalTrials.gov record · Yale University

At present, the treatment of Bipolar I disorder (BD-I), especially its depressive episode (bipolar depression), is still limited, because there is no effective treatment for the associated cognitive impairment and perceived stress. NMDA receptor (NMDAR) dysfunction is associated with BD-I, particularly its cognitive impairment and perceived stress.

NCT05977023 · Official ClinicalTrials.gov record · China Medical University Hospital

The goal of this clinical trial is to investigate the effects of ketamine, in combination with standard inpatient addiction therapy, for adults with depression and alcohol use disorder. After screening and enrollment, participants will undergo baseline assessments of depression, measures of alcohol use and craving, as well as neurocognitive function.

NCT06090422 · Official ClinicalTrials.gov record · University Hospital of North Norway

The goal of this naturalistic, open label, single arm intervention study is to investigate the effects of Esketamine in treating depression.The main aims to answer are: * to see if Esketamine is effective when added to ongoing antidepressant treatment * to identify patient characteristics that will determine a therapeutic response to Esketamine in real-world practice Participants will: * attend the clinic for supervised self-administration of intranasal Esketamine treatment * be observed for 2 hours following Esketamine administration including blood pressure monitoring * be asked to complete a battery of questionnaires * be reimbursed for travel expenses

NCT06103760 · Official ClinicalTrials.gov record · Royal North Shore Hospital

To learn about the feasibility, safety, and effects of psilocybin-assisted psychotherapy on depression and/or anxiety in participants who are being treated for advanced cancer.

NCT06200155 · Official ClinicalTrials.gov record · M.D. Anderson Cancer Center

Amyotrophic lateral sclerosis (ALS) is a progressive neurological disorder characterized by selective death of upper and lower motor neurons, which leads to severe disability and fatal outcomes. One of the major hallmarks of ALS is the denervation of neuromuscular junctions (NMJs), which is one of the earliest events seen in ALS patients and mouse models of ALS.

NCT06249867 · Official ClinicalTrials.gov record · Oliver Blanchard

The goal of this study is to assess Parenting STAIR Modular (PSTAIR-M), a promising and innovative intervention for military-connected mothers (MCM) who have experienced trauma and their young children (ages 2-10). PSTAIR-M aims to help mothers manage the strong feelings that sometimes happen after experiencing something scary or stressful, as well as to better connect with their children and manage their behavior effectively.

NCT06262178 · Official ClinicalTrials.gov record · New York University

The goal of this study is to compare the effectiveness of two formulations of ketamine - Spravato® and racemic ketamine - in people with treatment-resistant depression (TRD). The main questions it aims to answer are: * How the two formulations compare in terms of their effectiveness in treating TRD.

NCT06278779 · Official ClinicalTrials.gov record · The George Institute

The purpose of this trial is to determine if intermittent theta-burst stimulation (iTBS) can reduce the symptoms of depression in treatment-resistant bipolar disorder. To do this, some of the participants in this study will receive treatment with active iTBS stimulation, while others will receive sham iTBS stimulation.

NCT06370988 · Official ClinicalTrials.gov record · Centre for Addiction and Mental Health

This is a multicenter, randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment study in pediatric patients who are experiencing major depressive episodes (MDEs) associated with a primary diagnosis of bipolar I or bipolar II disorder as confirmed by Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL), according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5).

NCT06372964 · Official ClinicalTrials.gov record · Intra-Cellular Therapies, Inc.

The primary objective of this study is to investigate the safety, feasibility, and tolerability of psilocybin treatment in individuals with functional impairment due to psychiatric symptoms. The secondary objective of this study is to determine whether individuals with functional impairments due to psychiatric symptoms will experience statistically significant symptom reduction and functional improvement from baseline symptom measurements (Visit 3) to 1-week (Visit 7), 4-weeks (Visit 8), and 6-weeks (Visit 9) post dosing.

NCT06442423 · Official ClinicalTrials.gov record · Yale University

Mood disorders, such as depression and bipolar disorder, are difficult to treat. One reason is that there are no objective ways to measure how these disorders affect the body and respond to different treatments.

NCT06462196 · Official ClinicalTrials.gov record · National Institute of Mental Health (NIMH)

The core objective of this study is to enhance the translational potential of this electroencephalogram (EEG) biomarker by using ketamine(KET)-induced gamma potentiation as a prognostic marker of 4-week treatment outcome. Previous research focused exclusively on KET-induced gamma band potentiation (GBP) in the context of a single infusion.

NCT06480201 · Official ClinicalTrials.gov record · Texas A&M University

Depression is one of the most common mental disorders, affecting nearly 10% of men and 20% of women worldwide. It is associated with a significant increase in mortality, mainly due to suicidal behavior.

NCT06507787 · Official ClinicalTrials.gov record · Alcediag

Background: Major depressive disorder (major depression) is a serious mental illness that can put people at risk of self-harm and death. Many drugs are used to treat major depression, but it can take a long time for them to be effective.

NCT06511908 · Official ClinicalTrials.gov record · National Institute of Mental Health (NIMH)

Psilocybin, the chemical component of "magic mushrooms", has been administered with psychotherapy in several randomly assigned clinical trials (RCTs) showing large and sustained antidepressant effects. In healthy volunteers, the psychedelic effects of psilocybin have been shown to be blocked by administration of certain medications such as risperidone.

NCT06512220 · Official ClinicalTrials.gov record · Centre for Addiction and Mental Health

Psilocybin, the chemical component of "magic mushrooms", has been administered with psychotherapy in several randomly assigned clinical trials (RCTs) showing large and sustained antidepressant effects. this study wants to assess the feasibility, tolerability, and preliminary how well it works of psilocybin therapy for adults with chronic neuropathic pain and co-morbid treatment resistant depression.

NCT06518720 · Official ClinicalTrials.gov record · Centre for Addiction and Mental Health

The aim of this randomly assigned multicentre phase 2 clinical trial is to compare the effects of rTMS and SSRI medication as early treatment of depression. In this two-stage, therapy response-adapted trial, 106 patients suffering from non-treatment resistant major depression (non-TR MD) will be randomly assigned in Stage I to either 4 weeks bilateral theta burst stimulation (TBS) or 4 weeks antidepressant SSRI medication.

NCT06545474 · Official ClinicalTrials.gov record · University Hospital Tuebingen

The proposed study is a single-site, randomly assigned, controlled clinical trial (RCT) comparing ketamine-assisted psychotherapy (KAP) to a standard evidence-based regimen of ketamine administered in a medical model without psychotherapy (KET). Eligible study you would be adults with major depressive disorder (major depression).

NCT06559826 · Official ClinicalTrials.gov record · Icahn School of Medicine at Mount Sinai

This is an treatment, parallel arm assignment treatment study in individuals with Major Depressive Disorder (major depression). Each individual will be treated with a single dose of pimavanserin or dummy treatment (placebo) plus a single dose of psilocybin.

NCT06592833 · Official ClinicalTrials.gov record · Icahn School of Medicine at Mount Sinai

This is a pilot clinical trial to assess the feasibility, safety, and preliminary how well it works of ketamine-assisted group therapy for Spanish-speaking adults with depression

NCT06597695 · Official ClinicalTrials.gov record · Juliana Zambrano, MD, MPH

This study wants to assess antidepressant how well it works differences between ALTO-100 and dummy treatment (placebo) during the neither you nor the study doctors know who gets the real treatment period in patients with bipolar disorder I or II with current major depressive episode, when used adjunctively to a mood stabilizer and/or atypical antipsychotic, related to patient characteristics. Additionally, safety, tolerability, and how well it works will be assessed in a subsequent open label treatment period.

NCT06656416 · Official ClinicalTrials.gov record · Alto Neuroscience

This study wants to to measure the relationships between peak (% change from baseline) central GABA and Glu levels during a 40-min IV ketamine or normal saline infusion utilizing fMRS, and change in peripheral GABA and Glu levels from baseline to 24-hr postinfusion utilizing LCMS, with baseline to 24-hr post-infusion change in depression (MADRS) in 30 TRD adults.

NCT06668571 · Official ClinicalTrials.gov record · Mayo Clinic

The goal of this clinical trial is to learn if drug Rosuvastatin 10 mg works to treat major depression in adults. It will also learn about the safety of Rosuvastatin 10 mg .The main questions it aims to answer are: Does Rusovastatin lower the score of The Montgomery Asberg Depression Rating Scale (MADRS) among adult participants with Major Depression Disorder ( major depression )?

NCT06698666 · Official ClinicalTrials.gov record · Ain Shams University

This study wants to compare the relative effectiveness, acceptability, and side effects of ketamine delivered through an IV (a drip into the arm) which is not currently FDA approved for use in the treatment of treatment-resistant depression (TRD) and Esketamine (Spravato®), taken as a nasal spray which has received FDA approval for use in the treatment of treatment-resistant depression (TRD) in the treatment of patients with treatment-resistant depression (TRD). The study will look at the following: * How well the treatment helps with symptoms of depression (effectiveness), * How comfortable and willing people are to use the treatment (acceptability), and * How well people can deal with any side effects from the treatment (tolerability).

NCT06713616 · Official ClinicalTrials.gov record · Yale University

This watch-and-measure (no experimental treatment required) protocol is intended to provide long-term follow-up data on patients initiating or continuing treatment with either Spravato® or IV ketamine. This can provide us information on the patient acceptability and satisfaction, patterns of use, long-term effectiveness, and safety of the two approaches.

NCT06725277 · Official ClinicalTrials.gov record · Yale University

This study wants to identify pharmacokinetics of postpartum ketamine infusion. This study will assess ketamine kinetics and metabolism in this setting.

NCT06767566 · Official ClinicalTrials.gov record · University of Utah

Depression is a common condition, with serious negative effects on the health and quality of life of those affected. While there are currently various medications which attempt to treat depression, they often take a long time to begin to work and do not work at all for many people.

NCT06781697 · Official ClinicalTrials.gov record · Sunnybrook Health Sciences Centre

In the treatment of Major Depressive Disorder (major depression), ketamine can produce rapid but short-lasting improvements in mood. In order to develop a new generation of treatments with rapid and sustained how well it works, a better understanding of the mechanism of action is urgently needed.

NCT06788249 · Official ClinicalTrials.gov record · University of Pennsylvania

This study wants to determine the how well it works, whether it is safe and how hard side effects are to live with of CYB003 compared to matching dummy treatment (placebo) as added on top of your current treatment treatment in patients with major depression. For more information about the EMBRACE study, including participating study locations, and to register your interest in learning more about participation, please visit the study website: https://embrace-mdd-trial.com/

NCT06793397 · Official ClinicalTrials.gov record · Cybin IRL Limited

This clinical research study is to learn about the feasibility, safety, and effects of psilocybin-assisted psychotherapy for cancer survivors with depression and/or anxiety.

NCT06801041 · Official ClinicalTrials.gov record · M.D. Anderson Cancer Center

Pain is common in children presenting to the emergency department but is frequently undertreated, leading to both short- and long-term consequences. Morphine is the standard treatment for children with moderate to severe acute pain, but its use is associated with serious side effects and caregiver and clinician concerns related to opioid administration.

NCT06835504 · Official ClinicalTrials.gov record · Columbia University

The goal of this clinical trial is to treat active suicidal ideation in individuals with Major Depressive Disorder (major depression) using ketamine and to understand suicidal ideation by examining biological mechanisms using magnetic resonance imaging (MRI), and psychological mechanisms through validated clinical scales and qualitative interviews. The main questions it aims to answer are: 1.

NCT06891300 · Official ClinicalTrials.gov record · The Royal's Institute of Mental Health Research

The main objective of this randomly assigned clinical trial is to study if various modalities of brief (eight sessions) and ultra-brief (four sessions) transdiagnostic cognitive-behavioral treatment work for decrease emotional symptoms and disorders, as well as to find out which emotional regulation processes and common factor of the intervention itself are involved in the therapeutic improvement. The investigators will compare the interventions of four groups: ultra-brief group treatment (1), brief group treatment (2), ultra-brief individual treatment (3) with the ultra-brief relaxation (control) group.

NCT06909669 · Official ClinicalTrials.gov record · Universidad de Córdoba

Background: SARS-CoV-2 is the virus that causes COVID-19. Some people who recover from COVID-19 have long-term symptoms that affect the brain.

NCT06920628 · Official ClinicalTrials.gov record · National Institute of Mental Health (NIMH)

Fibromyalgia (FM) is a chronic disorder marked by widespread musculoskeletal pain, fatigue, sleep disturbances, and cognitive difficulties. Patients often experience hyperalgesia, allodynia, and muscle weakness.

NCT06923800 · Official ClinicalTrials.gov record · Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis

Post-thyroidectomy pain is a prevalent early postoperative complication. While pharmacological agents remain the mainstay of analgesia, their clinical application is constrained by adverse effects including nausea, respiratory depression, and gastrointestinal disturbances.

NCT06931743 · Official ClinicalTrials.gov record · Xiaonan Huang

We are studying the effect of a mind-body treatment for people with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) with or without Long COVID (LC). Our team recognizes that ME/CFS and Long COVID are serious, debilitating, biomedical conditions.

NCT06933173 · Official ClinicalTrials.gov record · University of Alberta

This study is a 12-week (in addition to up to 30 days of screening) randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment, parallel-group trial. The primary objective of this study is to assess the effectiveness, safety, and tolerability of single-dose psilocybin (25 mg)-assisted therapy in comparison to active dummy treatment (placebo) (1 mg micro-dose) psilocybin-assisted therapy in patients with bipolar II depression who have not responded to adequate trials with at least two first or second-line treatments for bipolar II depression (i.e.

NCT06943573 · Official ClinicalTrials.gov record · Lakshmi N Yatham

The indication of attention-deficit/hyperactivity disorder (ADHD) to be examined often occurs with other psychiatric disorders, and the majority of adults with ADHD have at least one psychiatric comorbidity in their lives. Depression is one of the most common comorbidities in patients with ADHD.

NCT06967857 · Official ClinicalTrials.gov record · Prof. Dr. Frank Behrens

This clinical trial tests how well a three-dimensional (3D) mindfulness virtual reality (VR) versus (vs) two-dimensional (2D) non-immersive interventions works in improving depression, anxiety, pain, and/or stress in patients with head and neck cancer (HNC) undergoing radiation or chemoradiation (C/RT), and their caregivers. HNC patients undergoing C/RT can experience higher levels of depression, anxiety, distress and pain that negatively impact their quality of life.

NCT06985784 · Official ClinicalTrials.gov record · City of Hope Medical Center

The purpose of this trial is to conduct an adequately powered clinical trial of once daily LFR for individuals diagnosed with treatment-resistant BD-DE who have not responded to iTBS or sham treatment applied to the left DLPFC. This work will develop the evidence supporting the use of LFR rTMS for individuals with treatment-resistant BD-DE who currently have limited treatment options to alleviate their suffering.

NCT06986460 · Official ClinicalTrials.gov record · Tyler Kaster

This study wants to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to cancer or other illnesses such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Parkinson's Disease (PD) or Idiopathic Pulmonary Fibrosis (IPF) as compared to active-dummy treatment (placebo).

NCT07002034 · Official ClinicalTrials.gov record · Reunion Neuroscience Inc

This is a randomly assigned, parallel-group, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment, this drug alone study to measure the how well it works, safety, and tolerability of SPT-300 (GlyphAllo) in adults with major depressive disorder (major depression), with or without anxious distress.

NCT07065240 · Official ClinicalTrials.gov record · Seaport Therapeutics

This study is assessing the how well it works and safety of NPX-5 in psilocybin-assisted psychotherapy for the treatment of adjustment disorder due to cancer diagnosis. This study is for people who are aged between 18 and 80 years old and suffer from anxiety after adjusting to an acutely stressful event of their cancer diagnosis.

NCT07072728 · Official ClinicalTrials.gov record · Psyence Australia Pty Ltd

This is mechanistic clinical trial that evaluates the role of one of the glutamate receptors (mGluR5) in cognitive behavioral therapy for insomnia (CBT-I) as a common pathway in improving sleep and depression.

NCT07076342 · Official ClinicalTrials.gov record · Stony Brook University

This is a randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment phase 3 clinical trial evaluating the additive effect of intravenous ketamine in combination with electroconvulsive therapy (ECT) in patients with treatment-resistant major depressive disorder (major depression). The study aims to determine whether ketamine enhances the antidepressant how well it works of ECT and reduces associated cognitive side effects.

NCT07088380 · Official ClinicalTrials.gov record · Università Vita-Salute San Raffaele

The goal of this study is to learn how psilocybin delivered with mindfulness-based therapy may help symptoms of posttraumatic stress disorder (PTSD). This is an assessor-blinded, randomly assigned, controlled study in participants with PTSD.

NCT07104916 · Official ClinicalTrials.gov record · Anthony P King

This is a monocentric, randomly assigned pilot study conducted at the Max Planck Institute of Psychiatry, Munich. The study investigates the effects of two different intermittent theta-burst stimulation (iTBS) schedules on biological and clinical outcomes in patients with depression and comorbid Post-COVID-19 condition (PCC).

NCT07197138 · Official ClinicalTrials.gov record · Max-Planck-Institute of Psychiatry

Psilocybin, a serotonin receptor agonist in the brain, significantly and quickly improves depressive symptoms while inducing profound acute subjective effects. The benefit-risk ratio of psilocybin in treatment-resistant depression seems favorable, but needs to be confirmed.

NCT07210112 · Official ClinicalTrials.gov record · Centre Hospitalier St Anne

This is a randomly assigned controlled trial investigating the effects of an 8-TRE intervention compared to a wait list (control) on metabolic health and body composition in people diagnosed with BD and who are currently obese and at least mildly depressed. Following a 1-week baseline assessment, you would be randomly assigned to either a TRE or the wait list (1-to-1 ratio) for 8 weeks.

NCT07211217 · Official ClinicalTrials.gov record · Massachusetts General Hospital

Low-income individuals have limited access to evidence-based interventions for mental health. Peer recovery specialists, individuals in recovery from mental health and/or substance use problems, have the potential to increase access to evidence-based interventions for individuals from low-resource communities, particularly when trained and supervised in models that are acceptable and feasible in these communities.

NCT07219394 · Official ClinicalTrials.gov record · Wayne State University

The purpose of this multi-site randomly assigned controlled trial is to measure the how well it works and risks of psilocybin for the treatment of depression in U.S. military Veterans with and without (±) concurrent posttraumatic stress disorder.

NCT07226232 · Official ClinicalTrials.gov record · VA Office of Research and Development

This study wants to evaluate how well JNJ-54135419 works (how well it works) in addition to comprehensive standard of care (SoC) in rapidly reducing the symptoms of major depressive disorder (major depression, a mental disorder characterized by a persistent feeling of sadness and loss of interest in activities) as compared with psychoactive dummy treatment (placebo) (does not contain JNJ-54135419) plus SoC in adolescent participants with acute suicidal ideation or behavior.

NCT07227454 · Official ClinicalTrials.gov record · Janssen Research & Development, LLC

This randomly assigned, neither you nor the study doctors know who gets the real treatment, sham-controlled clinical trial aims to measure the how well it works and underlying biological mechanisms of HD-tDCS targeting the primary somatosensory cortex in adolescents with bipolar depression. you would be randomly assigned to receive either active HD-tDCS or sham stimulation, in addition to routine clinical care.

NCT07246044 · Official ClinicalTrials.gov record · Jiangsu Province Nanjing Brain Hospital

The goal of this clinical trial is to learn if ACP-211 can help treat adults with major depressive disorder (major depression) who have not improved with antidepressant therapy (ADT), including those with treatment resistant depression (TRD). The main questions the study aims to answer are: * Does ACP-211 work better than a dummy treatment (placebo) (a look-alike capsule with no medicine) to reduce symptoms of depression?

NCT07284667 · Official ClinicalTrials.gov record · ACADIA Pharmaceuticals Inc.

Exercise has shown multiple beneficial effects in both healthy and post-stroke populations. One of these is the acute reduction in sensitivity to painful stimuli, called exercise-induced hypoalgesia (EIH).

NCT07327593 · Official ClinicalTrials.gov record · Neuron, Spain

Some adolescents experience periods of anxiety and/or depression, and some find that these periods return over time. this study wants to examine whether digital interventions-where individuals work systematically with their own thoughts and feelings during periods when they feel well-can help them maintain well-being for longer.

NCT07346911 · Official ClinicalTrials.gov record · University of Oslo

Using a 2-arm, RCT approach, the primary goal of the study is to measure the feasibility and preliminary how well it works of Inspiratory Muscle Strength Training (IMST) as a non-pharmacologic intervention to reduce cardiovascular and cognitive risks in older adults. Next, investigators will examine secondary effects of IMST on mood, sleep quality, systemic inflammation, and physical/motor function.

NCT07349706 · Official ClinicalTrials.gov record · Florida State University

Multiple sclerosis (MS), an inflammatory, neurodegenerative disease of the central nervous system, affects around 120,000 patients in France and is the leading cause of non-traumatic disability in young adults. It affects patients' health-related quality of life (QoL) and has a significant economic impact on patients and society as a whole.

NCT07372599 · Official ClinicalTrials.gov record · University Hospital, Caen

PTSD is a chronic mental health condition that drastically reduces an individual's quality of life Dextrose injection with a small needle has been used for chronic pain patients and watch-and-measure (no experimental treatment required) results have shown it to be effective in reducing anxiety, brain fog, and depression in patients with PTSD. This randomly assigned trial will compare dextrose injection with an injection control of normal saline (NS)

NCT07382596 · Official ClinicalTrials.gov record · Dr. Dean Reeves Clinic

The aim of this clinical trial is to investigate the effects of a three-week virtual reality-based cognitive remediation training (VR-CRT) programme in combination with daily intake of a histone deacetylase inhibitor (HDACi) sodium butyrate on cognition in symptomatically stable patients with mood (depression or bipolar disorder; MD) or schizophrenia spectrum disorders. The investigators hypothesize that the VR-based cognitive remediation training (VR-CRT) combined with HDACi butyrate vs.

NCT07404085 · Official ClinicalTrials.gov record · Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital

The goal of this clinical trial is to determine the safety and how well it works of psilocybin assisted Therapy (PAT) in individuals with comorbid Major Depressive Disorder (major depression) and Alcohol Use Disorder (AUD). The main question it aims to answer is: \- What is the feasibility and safety of administering PAT in adults with major depression-AUD by evaluating recruitment, retention, tolerability, and safety?

NCT07405606 · Official ClinicalTrials.gov record · Centre for Addiction and Mental Health

This study evaluates the safety and how well it works of brenipatide when administered with standard of care (SoC) compared to dummy treatment (placebo) plus SoC in delaying the return of major depressive symptoms. The trial is divided into four periods as follows: a screening period that will last approximately 1 month, a treatment period with a potential post treatment period that combined will last a minimum of 12 months, and the follow up period that will last approximately 2 months.

NCT07412756 · Official ClinicalTrials.gov record · Eli Lilly and Company

The ADAPT study is a single-site, Phase 2b, randomly assigned, quadruple-masked, compared with a dummy treatment trial evaluating an omega-3 dietary supplement enriched with specialized pro-resolving mediator (SPM) precursors in adults with chronic temporomandibular disorder (TMD) pain. The trial will enroll 100 adults aged 18 years or older with examiner-confirmed TMD myalgia or arthralgia will be enrolled at the University of North Carolina at Chapel Hill, Adams School of Dentistry.

NCT07437313 · Official ClinicalTrials.gov record · University of North Carolina, Chapel Hill

The goal of this clinical trial is to measure the effectiveness and cost-effectiveness of a digital mindfulness-based intervention in adults (aged 18-65) diagnosed with emotional disorders like depression or anxiety. The main questions it aims to answer are: * Does adding a digital mindfulness intervention to usual care help people recover from emotional disorders faster and more sustainably over two years?

NCT07458100 · Official ClinicalTrials.gov record · Peking University

This study aims to assess the impact of dupilumab on the mental health and quality of life of moderate-to-severe Atopic Dermatitis (AD) patients. The study will recruit participants from AD patients who are already receiving dupilumab treatment.

NCT07467564 · Official ClinicalTrials.gov record · Sanofi

This study wants to measure the effectiveness of the Syndemic-Adapted Medly Uganda (SAMU) in improving mental health care among adults living with HIV and hypertension in Uganda. In sub-Saharan Africa (SSA), there is a high prevalence of depression and anxiety among people living with HIV (PLHIV) as well as alcohol use disorder (AUD).

NCT07525271 · Official ClinicalTrials.gov record · Yale University

This study is being conducted at Massachusetts General Hospital (MGH) to explore whether adding psychedelic coaching can enhance the effects of ketamine or esketamine maintenance treatment in individuals with treatment-resistant depression (TRD). The investigators are currently enrolling participants who are receiving ongoing maintenance intravenous (IV) ketamine or intranasal esketamine (Spravato) treatment at the MGH Ketamine Clinic.

NCT07563868 · Official ClinicalTrials.gov record · Massachusetts General Hospital

The goal of this clinical trial is to learn if intravenous (IV) ketamine with Dialectical Behavioural Therapy (DBT) reduces suicidal ideation in individuals with suicidality who have been diagnosed with Borderline Personality Disorder and either Major Depressive Disorder or Bipolar Disorder. The main question it aims to answer is: Does IV ketamine and DBT produce more rapid and robust improvements in suicidal ideation (SI) severity between baseline and Day 35 compared to IV midazolam and DBT, as measured by changes in the Modified Scale for Suicidal Ideation (MSSI) scores ?

NCT07569198 · Official ClinicalTrials.gov record · Joshua Rosenblat

The goal of this prospective, multicenter, watch-and-measure (no experimental treatment required) cohort study is to measure the screening performance of blood-based biomarkers for Alzheimer's disease (AD) in a real-world community screening setting, and to establish the population baseline levels and reference intervals of these biomarkers in Chinese older adults. The main questions it aims to answer is: What is the clinical screening value of blood biomarkers (phosphorylated tau 217 to amyloid β 42 ratio \[pTau217/Aβ42\] and glial fibrillary acidic protein \[GFAP\]) for AD among community-dwelling older adults?

NCT07570719 · Official ClinicalTrials.gov record · Kuang XiaoJun

A Phase 3 neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to dummy treatment (placebo) in Major Depressive Disorder - Ascend

NCT07592689 · Official ClinicalTrials.gov record · Definium Therapeutics US, Inc.

The objective of this study is to measure the safety, tolerability, and preliminary how well it works of the Motif eXternally powered Cortical Stimulation (XCS) System when used as indicated for treatment-resistant depression (TRD).

NCT07594483 · Official ClinicalTrials.gov record · Motif Neurotech, Inc.

This study is for adults with major depressive disorder (depression) who are currently taking an SSRI or SNRI antidepressant but continue to experience anhedonia (reduced interest or pleasure) and emotional blunting. The study will test whether a single 25 mg dose of psilocybin, compared with dummy treatment (placebo), can improve these symptoms and improve the function of brain circuits involved in reward and motivation.

NCT07607938 · Official ClinicalTrials.gov record · NYU Langone Health

This study wants to understand whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy.

NCT07610369 · Official ClinicalTrials.gov record · Yale University

Since the COVID-19 pandemic, mental health disorders have increased significantly, particularly among young people. In France, the proportion of young people aged 18 to 25 suffering from depression almost doubled between 2017 and 2021.

NCT07618208 · Official ClinicalTrials.gov record · Assistance Publique - Hôpitaux de Paris

Depressive symptoms are common among patients admitted to the intensive care unit (ICU) and may adversely affect recovery, participation in care, treatment adherence, quality of life, and outcomes after critical illness. Conventional antidepressants have limited utility for rapidly treating depressive symptoms during an ICU admission because of their delayed onset of action and potential drug interactions in medically complex patients.

NCT07639359 · Official ClinicalTrials.gov record · Hospital Italiano de Buenos Aires

Among psychiatric disorders, bipolar disorder stands out due to its alarmingly high suicide rates. This condition presents unique management challenges, especially during its depressive phase, which carries the highest risk of suicide.

NCT07664852 · Official ClinicalTrials.gov record · Daniel Lindqvist

Depression is one of the leading causes of disability worldwide. Common treatments like antidepressant medications and talk therapy work well for some people, but many others do not improve, even after trying multiple treatments.

NCT07680140 · Official ClinicalTrials.gov record · Weill Medical College of Cornell University

Ketamine-Assisted Psychotherapy (KAP) is an innovative treatment that combines intravenous ketamine with psychotherapy in a carefully monitored clinical setting. At Senz, this treatment is being evaluated in an open-label clinical trial for individuals with persistent depression who have not responded sufficiently to previous treatments.

NCT07706478 · Official ClinicalTrials.gov record · Senz

This study wants to evaluate how well each individual dose of esketamine (56 milligrams \[mg\] and 84 mg) works when compared with dummy treatment (placebo) in improving depressive symptoms in participants with treatment resistant depression (individuals with major depressive disorder \[major depression\] who have not responded to at least 2 different antidepressant treatments given at an adequate dose for an adequate duration in the current episode of depression).

NCT07716098 · Official ClinicalTrials.gov record · Janssen Research & Development, LLC

This study addresses a critical unmet need in the treatment of bipolar disorder by investigating whether Subcallosal Cingulate (SCC) Deep Brain Stimulation (DBS) can safely and effectively treat treatment-resistant bipolar depression without inducing manic switches. The researchers propose to accomplish this by incorporating monitoring of the SCC local field potentials (LFP) for depression tracking and amygdala LFP monitoring for mania prediction while treating Bipolar I patients with SCC DBS Stimulation.

NCT07745374 · Official ClinicalTrials.gov record · Icahn School of Medicine at Mount Sinai

Standard Behavioral Parent Training (BPT) is often less effective for parents experiencing depression. As such, the Addressing Depression and Positive Parenting Techniques (ADAPT) intervention is a novel BPT tailored to address the unique emotional and cognitive needs of depressed parents to improve treatment outcomes.

NCT07749521 · Official ClinicalTrials.gov record · University of Toronto

The goal of this feasibility randomly assigned controlled trial is to assess the feasibility, acceptability, and demand, as well as preliminary effects of an evidence-based Intuitive Eating (IE) intervention among pregnant women who have obesity. The main research questions are: RQ1: What is the feasibility (acceptability and demand) of implementing an Intuitive Eating Intervention among pregnant and postpartum women?

NCT07792837 · Official ClinicalTrials.gov record · San Diego State University

The goal of this clinical trial is to see if combining ketamine with behavioral activation (BA) therapy to treat moderate to severe treatment-resistant depression improves depressive symptoms and general functioning more than ketamine alone. We aim to find out whether participants who receive both treatments: 1.

NCT07801703 · Official ClinicalTrials.gov record · The Royal's Institute of Mental Health Research

The goal of this study is to find out whether a comprehensive management program that uses a smart bracelet and a mobile app can help people who have had an ischemic stroke (a type of stroke caused by a blocked blood vessel in the brain) to prevent another stroke. The investigators also want to see whether this program helps with controlling blood pressure, blood sugar, and blood lipids, as well as with taking medications correctly, improving daily habits, and supporting emotional well-being.

NCT07825311 · Official ClinicalTrials.gov record · Affiliated Hospital of Nantong University

This prospective, single-arm, watch-and-measure (no experimental treatment required) pilot study evaluates a clinical decision support system developed by Singula Health for use in primary care. Adult patients complete a self-report assessment before a routine primary care visit.

NCT07834684 · Official ClinicalTrials.gov record · Singula Health, Inc.

The goal of this clinical trial is to learn if the anti-inflammatory medication adalimumab improves depressive symptoms in adults with Major Depressive Disorder (major depression) who are already taking the anti-depressant medication Lexapro (escitalopram). The main questions it aims to answer are: 1.

NCT07845604 · Official ClinicalTrials.gov record · Daniel Moriarity

Serotonin is a chemical in the brain that plays an important role in mood, sleep, and other functions. It works by attaching to different types of serotonin receptors on brain cells.

NCT07848477 · Official ClinicalTrials.gov record · University of Oxford

The goal of this watch-and-measure (no experimental treatment required) study is to measure the quality of life, drug safety and therapy compliance of schizophrenia or bipolar affective disorder patients during the treatment with quetiapine this drug alone or in combination with another antipsychotic/antipsychotics. The main outcome measures are: * quality of life using the World Health Organization Quality of Life questionnaire (WHOQOL) * safety through the monitoring of the incidence of possible adverse drug events by the researcher, with the assessment of the association between the administration of the drug and the occurrence of an adverse reaction * therapy adherence using the Medication Adherence Rating Scale (MARS).

NCT07858565 · Official ClinicalTrials.gov record · Bosnalijek D.D

The purpose of this research is to see if an experimental treatment for depression called intermittent theta burst stimulation (iTBS), a form of transcranial magnetic stimulation (TMS) can be improved for better results using electroencephalography (EEG) recordings (brain waves) for individuals with Major Depressive Disorder (major depression). This is a feasibility study to test a "closed-loop" procedure which guides the timing of this FDA-cleared form of TMS.

NCT07862205 · Official ClinicalTrials.gov record · Mayo Clinic

The goal of this clinical trial is to learn if a psychological program before surgery can help adults who have lasting stress from past medical experiences. It is for adults having planned, complex surgery on the digestive system, also called gastrointestinal (GI) surgery.

NCT07865052 · Official ClinicalTrials.gov record · Northwestern University

This single-center randomly assigned comparative study is designed to compare the effectiveness of tirzepatide and transcutaneous low-frequency auricular vagus nerve stimulation in adults with class I obesity and without chronic non-communicable diseases. The study focuses on changes in body weight, anthropometric indices, epicardial and visceral adipose tissue, body composition, behavioral factors, skeletal muscle characteristics, and cardiac structure and function.

NCT07866183 · Official ClinicalTrials.gov record · National Medical Research Center for Therapy and Preventive Medicine

The goal of this study is to learn whether people living with severe psychiatric disorders can be grouped into more homogeneous subgroups, across usual diagnostic categories, based on two key dimensions: social withdrawal and anhedonia (reduced ability to feel pleasure). The study includes adolescents and adults aged 15 to 60 with schizophrenia, a first psychotic episode, bipolar disorder, recurrent or treatment-resistant major depressive disorder, or autism spectrum disorder without intellectual disability, as well as healthy volunteers aged 18 to 60.

NCT07881016 · Official ClinicalTrials.gov record · Fondation FondaMental

This prospective watch-and-measure (no experimental treatment required) cohort study aims to investigate the association between preoperative multimorbidity burden and functional recovery after primary total knee arthroplasty (TKA) in patients with knee osteoarthritis. Approximately 230 adult patients undergoing elective unilateral primary TKA will be enrolled at a single hospital in Türkiye.

NCT07882316 · Official ClinicalTrials.gov record · Balikesir Ataturk City Hospital

The effect of aquatic exercise on central sensitization in patients with knee osteoarthritis are not fully known in the studies conducted to date. The aim of this study is to examine the effect of aquatic exercise on central sensitization and functional parameters in patients with knee osteoarthritis.

NCT07883824 · Official ClinicalTrials.gov record · Kirsehir Ahi Evran Universitesi

This study utilizes mobile health methods, including smartphone technology, subjective self-reports measures of emotion, behavioral tasks, functional Magnetic Resonance Imaging (fMRI), physiological measures of attention and arousal, and measures of health and social support to identify neural mechanisms associated with individual differences in the temporal course of emotional responses. The aim of this project is to utilize real-world and personally relevant events as stimuli to better understand how the temporal course of emotional responses relate to risk for developing mental disorders.

NCT07891624 · Official ClinicalTrials.gov record · University of Miami

This study aims to understand how anxiety disorders, depressive disorders, and bipolar disorder change over time and to identify patterns that may help with earlier recognition, diagnosis, and prediction of future symptoms. The study will enroll approximately 2,690 participants aged 12 to 55 years across multiple hospitals in China.

NCT07903246 · Official ClinicalTrials.gov record · Second Affiliated Hospital, Zhejiang University, School of Medicine

This study aims primarily to test target engagement of dupilumab by assessing changes in peripheral immune markers following interleukin-4 receptor alpha (IL-4Rα) blockade in adults with major depressive disorder (major depression). Secondary aims include evaluating safety, tolerability, feasibility, and open-label effects on depressive symptoms, blood-based immune markers, blood-brain barrier (BBB) function, and functional brain reward circuitry.

NCT07908563 · Official ClinicalTrials.gov record · Icahn School of Medicine at Mount Sinai

The goal of this clinical trial is to measure the how well it works of a 5-day short-course external trigeminal nerve stimulation (eTNS) regimen in patients with acute ischemic stroke. The main questions it aims to answer are whether a 5-day eTNS intervention can significantly improve the neurological response rate at Day 30 compared to sham stimulation, and whether this short-course treatment yields sustained improvements in neuropsychiatric symptoms (depression, anxiety, and insomnia) over a 90-day follow-up period.

NCT07911605 · Official ClinicalTrials.gov record · Xidian University

This study will compare inspiratory muscle training and diaphragmatic breathing exercises in individuals with generalized anxiety disorder (GAD). It aims to see if adding either breathing-based intervention to a combined exercise program improves anxiety symptoms and other health-related outcomes compared with adding progressive muscle relaxation.

NCT07913503 · Official ClinicalTrials.gov record · Saglik Bilimleri Universitesi

The aim of this clinical trial is to investigate the effects of a six-week targeted affective cognitive training, combining virtual reality and computer-based exercises, in symptomatically stable patients with mood disorders (major depressive disorder or bipolar disorder) and unaffected first-degree relatives. The investigators hypothesize that targeted affective cognitive training, compared with treatment as usual, will improve affective cognition (primary outcome), assessed using a composite measure of emotion regulation and facial emotion recognition.

NCT07920302 · Official ClinicalTrials.gov record · Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital

Cannabis use disorder (CUD) and major depressive disorder (major depression) are among the most prevalent psychiatric conditions in the United States, affecting an estimated 20.6 million and 21 million adults respectively. Both disorders are characterized by anhedonia, diminished motivation, and blunted neural reward sensitivity.

NCT07924852 · Official ClinicalTrials.gov record · Florida State University

Temporally interfering (TI) electrical stimulation is a novel noninvasive neuromodulation technique with high spatial resolution. Although its effects on human brain function and behavior have been increasingly investigated, its clinical utility in major depressive disorder (major depression) has not been established.

NCT07924917 · Official ClinicalTrials.gov record · Tianjin Medical University General Hospital

The goal of this watch-and-measure (no experimental treatment required) study is to investigate emotional recognition and emotional reactivity in individuals with severe Alcohol Use Disorder (sAUD), Major Depressive Disorder (major depression), comorbid sAUD and depressive symptoms (sAUD+DS), and healthy controls. The main questions this study aims to answer are: * Do individuals with sAUD, major depression, sAUD+DS, and healthy controls exhibit different patterns of emotional recognition and emotional reactivity in response to dynamic emotional stimuli?

NCT07925281 · Official ClinicalTrials.gov record · Université Catholique de Louvain